激素补充治疗围绝经期综合征的利和弊被引量：3

The benefits and risks of hormone replacement therapy for perimenopausal syndrome

下载PDF

导出

摘要雌激素在女性一生中起着重要的作用,影响女性全身多个系统。绝经后雌激素缺乏导致围绝经期症状及某些老年慢性疾病风险增加,激素补充治疗(hormone replacement therapy,HRT)是目前最有效、最全面地治疗围绝经期雌激素降低所致相关症状的治疗方法。证据表明,在治疗窗口期启动,并按照规范合理使用HRT,掌握适应证、禁忌证和慎用情况是利大于弊的。现今中国绝经后女性人口众多,但对HRT的知晓率低,宣传普及绝经知识、探索更加安全的HRT方案将是我们妇产科医师努力的方向。

作者李萍倪婕史颖莉

机构地区南京医科大学附属南京妇幼保健院

出处《药品评价》 CAS 2014年第7期8-10,14,共4页 Drug Evaluation

关键词围绝经期综合征激素补充治疗治疗利弊

分类号 R711.75 [医药卫生—妇产科学]

引文网络
相关文献

参考文献11

1Reichman WE, Rose NS. History and experience: the direction of Alzheimer's disease[J]. Menopause, 2012, 19(7): 724-734.
2郁琦,尚梦远.绝经相关激素补充治疗现状[J].实用妇产科杂志,2013,29(2):81-83. 被引量：28
3绝经过渡期和绝经后期激素补充治疗临床应用指南（2009版）[J].中华妇产科杂志,2010,45(8):635-638. 被引量：136
4de Villiers T J, Stevenson JC. The WHI: the effect of hormone replacement therapy on fracture prevention[J]. Climacteric, 2012 Jun, 15(3): 263-266.
5Gass ML, Heights M, Manson JE, et al. The 2012hormonetherapypositio nstatement of: The North American Menopause Society[J]. Menopause, 2012, 19(3): 257-271.
6Farquhar C, Marjoribanks J, Roberts H, et al. Long term hormone therapy for perimenopausal and postmenopausal women[J]. Cochrane Database Syst Rev, 2009 Apr 15, (2): CD004143.
7Nelson HD, Walker M, Zakher B, et al. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. preventive services task force recommendations [J]. Ann Intern Med, 2012, 157(2): 104-113.
8Reckelhoff JF, Maric C. Sex and gender differences in cardiovascular- renal physiology and pathophysiology[J]. Steroids, 2010 Nov, 75(11): 745-746.
9Rosano GM, Vitale C, Fini M. Cardiovascular aspects of menopausal hor-mone replacement therapy[J]. Climacteric, 2009, 12(Suppll): 41-46.
10Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease[J]. N Engl J Med, 2003, 349(6): 523-534.

二级参考文献14

1夏建红,田丰莲,赵庆国,何少兰.围绝经期妇女就诊及激素替代治疗态度调查[J].中国公共卫生,2005,21(1):83-84. 被引量：39
2Board of the International Menopause Society,Pines A,Sturdee DW,et al.IMS updated recommendations on postmenopausal hormone therapy.Climacteric,2007,10:181-194.
3Gompel A,Rozenberg S,Barlow DH,et al.The EMAS 2008update on clinical recommendations on postmenopausal hormone replacement therapy.Maturitas,2008,61:227-232.
4Utian WH,Archer DF,Bachmann GA,et al.Estrogen and progestogen use in postmenopausal women:July 2008 position statement of The North American Menopause Society.Menopause,2008,15:584-602.
5North American Menopause Society.The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women:2007 position statement of The North American Menopause Society.Menopause,2007,14:355-369.
6APMF 2008 Consensus Statement on the Management of the Menopause[DB/OL] .[2010-7-2] .http://www.apmf.net/news/.
7中国卫生部.2012年中国卫生统计提要[EB/OL].http://www.moh.gov.cn/mohwsbwstjxxzx/s7967/201206/55044.shtml.
8Stephen H, Curt F, Elizabeth BC, et al. Noncardiovascular disease out- comes during 6. 8 years of hormone therapy heart and estrogen/pro- gestin replacement study follow-up( HERS 11 ) [ J]. JAMA ,2002,288 (1) :58 -66.
9Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: princip'al and results from the women's health initiative randomized controlled trial[ J], JAMA ,2002,288 (3) :321 - 333.
10Vankrunkelsven P, kellen E, Lousbergh D, et al. Reduction in hor- mone replacement therapy use and declining breast cancer incidence the belgian province of limburg[ J]. Breast Cancer Res Treat,2009, 118(2) :425 -432.